Clinical Trials Browser

Lung Neoplasms

NCT05681039 2026-03-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2 Recruiting

29 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06754501 2026-02-18

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Phase 2 Active not recruiting

4 enrolled

Tumor-Agnostic

Neoplasms

NCT04958811 2026-01-26

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Phase 2 Active not recruiting

29 enrolled

Thoracic

Lung Neoplasms

NCT05746481 2026-01-22

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Phase 2 Terminated

3 enrolled 12 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06784947 2025-10-02

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Phase 2 Active not recruiting

13 enrolled

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03977467 2025-08-27

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Phase 2 Completed

46 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05825625 2025-05-23

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Phase 2 Active not recruiting

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05483400 2025-03-30

TIRACAN

Phase 2 Recruiting

97 enrolled

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma

NCT03708224 2025-01-28

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Phase 2 Recruiting

55 enrolled

Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

NCT06003621 2024-11-15

MoST-TAP

Phase 2 Recruiting

96 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06342037 2024-09-19

TONIC-3

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05060003 2024-02-20

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Phase 2 Terminated

7 enrolled 4 charts

Dermatologic

Melanoma

NCT05034055 2021-09-05

SKYROCKET

Phase 2 Unknown

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

INDIGO

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

TIRACAN

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

MoST-TAP

TONIC-3

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

SKYROCKET